News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AstraZeneca PLC (AZN) Eyes Bigger Deals to Fill the Pipeline


3/9/2012 7:52:12 AM

AstraZeneca (AZN.L) is dusting off its cheque book. The country's second biggest drugmaker has bought nothing for more than $400 million (253 million pounds) since its 2007 purchase of U.S. biotechnology company MedImmune for $15.6 billion -- an overpriced flop that has failed to deliver. Now, its drug pipeline down to a trickle, the company is venturing back into the market and aiming for multiple low-billion-dollar deals. "We are very actively talking to a number of companies, including potential peer-to-peer and biotech deals," research head Martin Mackay, whose job it is to find tomorrow's big sellers, told Reuters.

Read at Reuters


comments powered by Disqus
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES